AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22820158 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise session
Number of subjects: 30
Study 22820158 — intervention group
Group type: COMPARATOR
Intervention: Baseline assessment
Number of subjects: 30
Study 19887674 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (selective COX-2 inhibitor)
Number of subjects: 41
Study 19887674 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (100 mg/day)
Number of subjects: 41
Study 19887674 — intervention group
Group type: EXPERIMENTAL
Intervention: NS-398 (selective COX-2 inhibitor) added in vitro
Number of subjects: 41
Study 18248356 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D guidance
Number of subjects: 30
Study 18248356 — intervention group
Group type: COMPARATOR
Intervention: 3D angioscopy
Number of subjects: 30
Study 18248356 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS multivessel intervention
Number of subjects: 30
Study 18248356 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic guided intervention
Number of subjects: 30
Study 18248356 — intervention group
Group type: EXPERIMENTAL
Intervention: MNS
Number of subjects: 30
Study 15817865 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based therapy with RUTF
Number of subjects: 1178
Study 15817865 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 1178
Study 14728493 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-accessible electronic medical record
Number of subjects: 0
Study 14728493 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10643835 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen Replacement Therapy (ERT)
Number of subjects: 23
Study 8876406 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme for nurses
Number of subjects: 0
Study 1445513 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic (hydrochlorothiazide 25 mg or 50 mg plus amiloride 2.5 mg or 5 mg daily)
Number of subjects: 4396
Study 1445513 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta blocker (atenolol 50 mg daily)
Number of subjects: 4396
Study 1445513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4396
Study 4061343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg zinc added to daily vitamin and mineral supplements)
Number of subjects: 138
Study 4061343 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar daily vitamin and mineral supplements without zinc)
Number of subjects: 138
Study 4061343 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 138
Study 31796025 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual azithromycin distribution
Number of subjects: 991
Study 31796025 — intervention group
Group type: COMPARATOR
Intervention: Annual azithromycin distribution
Number of subjects: 991
Study 30236795 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based APP (TRAFIC) for electronic PROMs collection
Number of subjects: 100
Study 30236795 — intervention group
Group type: COMPARATOR
Intervention: Control group (not utilizing the APP)
Number of subjects: 100
Study 27510346 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing within 30 days of a positive STI test
Number of subjects: 15260
Study 27510346 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing within 90 days of a positive STI test
Number of subjects: 15260
Study 27510346 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis testing within 30 days of a positive STI test
Number of subjects: 15260
Study 27510346 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV testing within 30 days of syphilis testing
Number of subjects: 15260
Study 24849434 — intervention group
Group type: EXPERIMENTAL
Intervention: DC-CIK immunotherapy combined with TACE
Number of subjects: 68
Study 24849434 — intervention group
Group type: COMPARATOR
Intervention: TACE alone (control group)
Number of subjects: 68
Study 22984155 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl 25 µg
Number of subjects: 10
Study 22984155 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl 25 µg
Number of subjects: 10
Study 22984155 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fentanyl (50 to 300 µg)
Number of subjects: 10
Study 20819419 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal instillation of 2 mg/kg ropivacaine
Number of subjects: 63
Study 20819419 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (placebo control)
Number of subjects: 63
Study 18281049 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin treatment for 3 months
Number of subjects: 44
Study 18281049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol-cyproterone acetate (EE/CPA) treatment for 3 months
Number of subjects: 44
Study 18281049 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 44
Study 15309436 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B(6), B(12), and folate supplementation for 6 months
Number of subjects: 220
Study 15309436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 220
Study 12421488 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg/day
Number of subjects: 211
Study 12421488 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg/day
Number of subjects: 211
Study 10598759 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 5-aminolaevulinic acid photodynamic therapy (ALA-PDT)
Number of subjects: 10
Study 7564784 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha (6 MU three times weekly for 12‐24 weeks)
Number of subjects: 90
Study 7564784 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN‐alpha
Number of subjects: 90
Study 7564784 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 90
Study 1940881 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma interferon (0.5 to 3.0 million units per day for 7 days)
Number of subjects: 35
Study 1940881 — intervention group
Group type: COMPARATOR
Intervention: Alpha interferon (5-6 million units daily)
Number of subjects: 35
Study 1940881 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma interferon (1 million units for 28 consecutive days)
Number of subjects: 35
Study 1940881 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFNs
Number of subjects: 35
Study 1940881 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma interferon
Number of subjects: 35
Study 6412584 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 4 micrograms/kg
Number of subjects: 10
Study 6412584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6412584 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 5 mg
Number of subjects: 10
Study 6412584 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 5 mg
Number of subjects: 10
Study 6412584 — intervention group
Group type: COMPARATOR
Intervention: Etomidate 10 mg
Number of subjects: 10
Study 29553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Box + Good Behavior Game (GBG)
Number of subjects: 0
Study 29553287 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Box
Number of subjects: 0
Study 29553287 — intervention group
Group type: COMPARATOR
Intervention: Control (typical classroom management techniques)
Number of subjects: 0
Study 30346560 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified S-1 treatment (reduced initial dose of S-1 by ≥ 1 level compared with the standard dose)
Number of subjects: 370
Study 30346560 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 370
Study 26176649 — intervention group
Group type: EXPERIMENTAL
Intervention: Hot compresses (40°C) applied to the lumbar area for 5 hours daily for 2 weeks
Number of subjects: 39
Study 26176649 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 24854458 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended release niacin (ERN)
Number of subjects: 327
Study 24854458 — intervention group
Group type: COMPARATOR
Intervention: Extended release niacin combined with laropiprant (ERN-L)
Number of subjects: 327
Study 24854458 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 327
Study 22963328 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal training intervention (MTI) consisting of daily endurance and twice-a-week strength training
Number of subjects: 117
Study 22963328 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal training intervention (MTI)
Number of subjects: 117
Study 19343362 — intervention group
Group type: EXPERIMENTAL
Intervention: Coconut and anise spray
Number of subjects: 100
Study 19343362 — intervention group
Group type: COMPARATOR
Intervention: Permethrin 0.43% lotion
Number of subjects: 100
Study 17914654 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 49
Study 17914654 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulation
Number of subjects: 49
Study 15935095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 10 mg
Number of subjects: 465
Study 15935095 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Number of subjects: 465
Study 15935095 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 10 mg
Number of subjects: 465
Study 15935095 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin
Number of subjects: 465
Study 12423713 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (high-dose, 1-year course)
Number of subjects: 82
Study 12423713 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (high-dose, 1-year course)
Number of subjects: 82
Study 12423713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 10437298 — intervention group
Group type: EXPERIMENTAL
Intervention: Bracing for Cobb angle over thirty degrees
Number of subjects: 0
Study 10437298 — intervention group
Group type: COMPARATOR
Intervention: Natural history of scoliosis
Number of subjects: 0
Study 10437298 — intervention group
Group type: COMPARATOR
Intervention: Scoliotic population
Number of subjects: 0
Study 10437298 — intervention group
Group type: COMPARATOR
Intervention: Non-operated patients with severe idiopathic scoliosis
Number of subjects: 0
Study 10437298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-hooks systems for surgical correction
Number of subjects: 0
Study 8584309 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined diphtheria-tetanus vaccine administered at 3, 5, and 12 months of age.
Number of subjects: 44
Study 2218781 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoramin
Number of subjects: 60
Study 2218781 — intervention group
Group type: COMPARATOR
Intervention: Alpha-methyldopa
Number of subjects: 60
Study 2218781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 7005521 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 70
Study 7005521 — intervention group
Group type: COMPARATOR
Intervention: D-Penicillamine (D-Pen.)
Number of subjects: 70
Study 30365024 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported e‐cig use (times per day)
Number of subjects: 259
Study 30365024 — intervention group
Group type: EXPERIMENTAL
Intervention: Penn State Electronic Cigarette Dependence Index (PSECDI)
Number of subjects: 259
Study 30149476 — intervention group
Group type: EXPERIMENTAL
Intervention: VEGF protein expression in the proximal end of the umbilical cord
Number of subjects: 48
Study 30149476 — intervention group
Group type: COMPARATOR
Intervention: VEGF protein expression in the distal end of the umbilical cord
Number of subjects: 48
Study 29071332 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing ticagrelor, 180mg
Number of subjects: 50
Study 29071332 — intervention group
Group type: COMPARATOR
Intervention: Standard oral administration of ticagrelor, 180mg
Number of subjects: 50
Study 29071332 — intervention group
Group type: COMPARATOR
Intervention: Both groups (chewing and standard oral administration)
Number of subjects: 50
Study 25465884 — intervention group
Group type: EXPERIMENTAL
Intervention: Social stress condition
Number of subjects: 35
Study 25465884 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 23949042 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Kinetic Chain (CKC) exercise
Number of subjects: 33
Study 23949042 — intervention group
Group type: EXPERIMENTAL
Intervention: Open Kinetic Chain (OKC) exercise
Number of subjects: 33
Study 23949042 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine activities, no exercise)
Number of subjects: 33
Study 21051511 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic brain volume assessment using Q(Brain) software
Number of subjects: 61
Study 21051511 — intervention group
Group type: COMPARATOR
Intervention: Manual brain volume assessment (reference method)
Number of subjects: 61
Study 19592125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 0
Study 19592125 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 0
Study 17466465 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention designed to decrease sexual and injection risk behaviors, delivered in six sessions.
Number of subjects: 0
Study 17466465 — intervention group
Group type: COMPARATOR
Intervention: Control intervention, details not specified.
Number of subjects: 0
Study 14984453 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin aspart (0.15 U/kg body weight)
Number of subjects: 23
Study 14984453 — intervention group
Group type: COMPARATOR
Intervention: Regular insulin (0.15 U/kg body weight)
Number of subjects: 23
Study 14984453 — intervention group
Group type: COMPARATOR
Intervention: Normal controls (single standard meal test)
Number of subjects: 23
Study 11157184 — intervention group
Group type: COMPARATOR
Intervention: AR-R15896AR 250 mg loading dose
Number of subjects: 175
Study 11157184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 175
Study 11157184 — intervention group
Group type: COMPARATOR
Intervention: AR-R15896AR 120 mg maintenance dose
Number of subjects: 175
Study 10923526 — intervention group
Group type: EXPERIMENTAL
Intervention: Urban children
Number of subjects: 157362
Study 10923526 — intervention group
Group type: EXPERIMENTAL
Intervention: Rural children
Number of subjects: 157362
Study 10923526 — intervention group
Group type: EXPERIMENTAL
Intervention: Children in northern and central China
Number of subjects: 157362
Study 10923526 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall children
Number of subjects: 157362
Study 7939467 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic ligature of the spermatic veins (outpatient group)
Number of subjects: 24
Study 7939467 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ligature of the spermatic veins (hospitalised group)
Number of subjects: 24
Study 3047887 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 2.5 mg
Number of subjects: 0
Study 3047887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29899342 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-occurrence scenario
Number of subjects: 130
Study 29899342 — intervention group
Group type: COMPARATOR
Intervention: Trait information scenario
Number of subjects: 130
Study 29899342 — intervention group
Group type: COMPARATOR
Intervention: Random selection scenario
Number of subjects: 130
Study 27364771 — intervention group
Group type: EXPERIMENTAL
Intervention: Veledimex (oral activator ligand) administered in Labrasol slurry and F-22 capsule formulations
Number of subjects: 0
Study 27364771 — intervention group
Group type: EXPERIMENTAL
Intervention: Veledimex (oral activator ligand) administered once daily for 14 days
Number of subjects: 0
Study 27364771 — intervention group
Group type: EXPERIMENTAL
Intervention: Veledimex taken under fed conditions
Number of subjects: 0
Study 27364771 — intervention group
Group type: EXPERIMENTAL
Intervention: Veledimex (overall treatment)
Number of subjects: 0
Study 26582847 — intervention group
Group type: EXPERIMENTAL
Intervention: PTC1‐2 group (post‐tetanic counts 1‐2)
Number of subjects: 72
Study 26582847 — intervention group
Group type: COMPARATOR
Intervention: TOFcount1‐2 group (train‐of‐four counts 1‐2)
Number of subjects: 72
Study 24250307 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet regimen, exercise training, and medical treatment for two months
Number of subjects: 80
Study 24250307 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment only
Number of subjects: 80
Study 20333393 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Misgav-Ladach method (MMLM)
Number of subjects: 115
Study 20333393 — intervention group
Group type: COMPARATOR
Intervention: Pfannenstiel-Kerr method (PKM)
Number of subjects: 115
Study 20333393 — intervention group
Group type: EXPERIMENTAL
Intervention: Both MMLM and PKM
Number of subjects: 115
Study 18344107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release acetaminophen, 1300 mg orally q8h for 11 doses
Number of subjects: 52
Study 18344107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 17292769 — intervention group
Group type: EXPERIMENTAL
Intervention: artemether-lumefantrine
Number of subjects: 521
Study 17292769 — intervention group
Group type: COMPARATOR
Intervention: amodiaquine plus sulfadoxine-pyrimethamine
Number of subjects: 521
Study 14969673 — intervention group
Group type: COMPARATOR
Intervention: Family-planning (FP) referral
Number of subjects: 474
Study 14969673 — intervention group
Group type: COMPARATOR
Intervention: Advanced provision emergency contraception (APEC)
Number of subjects: 474
Study 14969673 — intervention group
Group type: COMPARATOR
Intervention: Past pregnancy rate
Number of subjects: 474
Study 14969673 — intervention group
Group type: COMPARATOR
Intervention: No contraception or condoms alone
Number of subjects: 474
Study 11878530 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% gelatin solution (Gelofusine) 15 ml kg(‐1) i.v. (colloid group)
Number of subjects: 68
Study 11878530 — intervention group
Group type: COMPARATOR
Intervention: No preload (control group)
Number of subjects: 68
Study 9181155 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg hyperbaric lidocaine 5%
Number of subjects: 20
Study 9181155 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg hyperbaric lidocaine 5%
Number of subjects: 20
Study 9181155 — intervention group
Group type: COMPARATOR
Intervention: Both dosage groups (75 mg and 100 mg)
Number of subjects: 20
Study 7964106 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled active motion regimen
Number of subjects: 0
Study 7964106 — intervention group
Group type: COMPARATOR
Intervention: Passive flexion-active extension regimen
Number of subjects: 0
Study 3596336 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg nocte
Number of subjects: 21
Study 3596336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 2 X 150 mg per day
Number of subjects: 21
Study 3596336 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg nocte
Number of subjects: 21
Study 3596336 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 30526588 — intervention group
Group type: EXPERIMENTAL
Intervention: Two rounds of mass drug administration (MDA) with dihydroartemisinin‐piperaquine and single low‐dose primaquine, administered 4 weeks apart in May‐June 2016.
Number of subjects: 21000
Study 30526588 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 21000
Study 26583280 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-modified Jones tube injector (Gunther Weiss Scientific Glass)
Number of subjects: 18
Study 26583280 — intervention group
Group type: COMPARATOR
Intervention: Closed-system intraocular lens injector (Viscoject 2.2; Medicel)
Number of subjects: 18
Study 23243978 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer PowerGel (GLU; glutaraldehyde/HEMA)
Number of subjects: 50
Study 23243978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; water)
Number of subjects: 50
Study 23243978 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock (BIS; oxalate)
Number of subjects: 50
Study 21143839 — intervention group
Group type: EXPERIMENTAL
Intervention: rs1044925 polymorphism in the ACAT-1 gene in Bai Ku Yao females
Number of subjects: 1250
Study 21143839 — intervention group
Group type: EXPERIMENTAL
Intervention: C allele carriers in Bai Ku Yao
Number of subjects: 1250
Study 21143839 — intervention group
Group type: COMPARATOR
Intervention: rs1044925 polymorphism in the ACAT-1 gene in Han population
Number of subjects: 1250
Study 18402714 — intervention group
Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 391
Study 18402714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 15618781 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin (1 mg)
Number of subjects: 32
Study 15618781 — intervention group
Group type: COMPARATOR
Intervention: Norepinephrine infusion
Number of subjects: 32
Study 11875582 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate (10 mmol) infusion
Number of subjects: 22
Study 11875582 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 22
Study 10448830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP) 23‐35 mg/kg/day, t.i.d.
Number of subjects: 247
Study 10448830 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 247
Study 10448830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 247
Study 7799699 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate
Number of subjects: 10
Study 7799699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2149388 — intervention group
Group type: EXPERIMENTAL
Intervention: cilazapril (2.5 to 5.0 mg)
Number of subjects: 30
Study 2149388 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (25 to 50 mg)
Number of subjects: 30
Study 364285 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of vincristine and prednisone with streptonigrin
Number of subjects: 0
Study 364285 — intervention group
Group type: COMPARATOR
Intervention: Combination of vincristine and prednisone with cyclophosphamide
Number of subjects: 0
Study 364285 — intervention group
Group type: EXPERIMENTAL
Intervention: Remission maintenance with cyclophosphamide
Number of subjects: 0